Longeveron Inc. Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
March 10, 2023 08:00 ET
|
Longeveron
-- Full results from ELPIS I trial published in European Heart Journal Open – -- First patient to be randomized in Japan Aging-Related Phase 2 study in Q1 – ...
Longeveron to Announce Fourth Quarter and Full Year Financial Results on March 10, 2023
March 06, 2023 08:30 ET
|
Longeveron
MIAMI, March 06, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical...
Longeveron Appoints Wa’el Hashad as Chief Executive Officer
February 28, 2023 08:30 ET
|
Longeveron
Hashad is a former executive at Avanir, Amgen, Boehringer Ingelheim, Eli Lilly, and early-stage biotechnology companies Global leader brings over 35 years of experience with focus on drug approval...
Longeveron Announces Publication of Final Data from ELPIS I Trial of Lomecel-BTM for Hypoplastic Left Heart Syndrome in Peer-Reviewed Journal
January 19, 2023 08:30 ET
|
Longeveron
-- Full results published in European Heart Journal Open -- -- Study met primary safety endpoint -- -- All patients alive, transplant-free, and maintained expected rate of growth one year...
UPDATE -- Longeveron Provides Corporate Update and Announces 2023 Strategic Priorities and Anticipated Milestones
January 06, 2023 09:58 ET
|
Longeveron
– Expects to enroll first patient in Phase 2 clinical trial of Lomecel-B™ for Aging-Related Frailty in Japan in 1Q23 – – Extended cash runway into 2H24 – MIAMI, Jan. 06, 2023 (GLOBE NEWSWIRE) --...
Longeveron Provides Corporate Update and Announces 2023 Strategic Priorities and Anticipated Milestones
January 06, 2023 08:30 ET
|
Longeveron
– Expects to enroll first patient in Phase 2 clinical trial of Lomecel-B™ for Aging-Related Frailty in Japan in 1Q23 – – Extended cash runway into 2H24 – MIAMI, Jan. 06, 2023 (GLOBE NEWSWIRE) --...
Longeveron to Participate in Upcoming 2022 Investor Conferences
November 29, 2022 16:30 ET
|
Longeveron
MIAMI, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs,...
Longeveron Inc. Provides Corporate Update and Reports Third Quarter 2022 Financial Results
November 14, 2022 08:00 ET
|
Longeveron
-- Achieved key clinical and regulatory milestones across clinical pipeline, including the completion of enrollment in Longeveron’s Phase 2a trial for Alzheimer’s Disease -- -- Conference call...
Longeveron Announces Completion of Enrollment in Phase 2a Trial of Lomecel-B™ for the Treatment of Alzheimer’s Disease
November 10, 2022 08:30 ET
|
Longeveron
MIAMI, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs,...
Longeveron to Announce Third Quarter 2022 Financial Results on November 14, 2022
November 07, 2022 09:06 ET
|
Longeveron
MIAMI, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs,...